Citizens Financial Group Inc. RI Invests $1.67 Million in Halozyme Therapeutics, Inc. $HALO

Citizens Financial Group Inc. RI bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 25,822 shares of the biopharmaceutical company’s stock, valued at approximately $1,669,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Fifth Third Bancorp lifted its holdings in Halozyme Therapeutics by 4,206.4% in the first quarter. Fifth Third Bancorp now owns 68,128 shares of the biopharmaceutical company’s stock valued at $4,403,000 after acquiring an additional 66,546 shares during the last quarter. Bernzott Capital Advisors grew its position in Halozyme Therapeutics by 0.7% in the first quarter. Bernzott Capital Advisors now owns 68,277 shares of the biopharmaceutical company’s stock worth $4,413,000 after acquiring an additional 483 shares during the period. Graetz Wealth LLC acquired a new stake in Halozyme Therapeutics during the first quarter worth $231,000. Granite Investment Partners LLC increased its stake in Halozyme Therapeutics by 76.5% during the first quarter. Granite Investment Partners LLC now owns 51,719 shares of the biopharmaceutical company’s stock worth $3,343,000 after acquiring an additional 22,419 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in Halozyme Therapeutics by 27.1% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 10,800 shares of the biopharmaceutical company’s stock valued at $698,000 after purchasing an additional 2,300 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

HALO stock opened at $76.11 on Tuesday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The firm has a market capitalization of $9.03 billion, a P/E ratio of 27.38, a P/E/G ratio of 0.32 and a beta of 0.84. The business’s 50-day moving average is $71.14 and its two-hundred day moving average is $69.98. Halozyme Therapeutics, Inc. has a 1 year low of $55.64 and a 1 year high of $82.26.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $55,088,215. This trade represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the transaction, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 74,102 shares of company stock valued at $5,205,798. 2.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on HALO shares. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.